Abstract Details

Title MRI and Clinical Predictors in Multiple Sclerosis: 9 Year Follow-Up Study

Topic MS and Related Diseases

Presentation(s) S10 - (-)

Poster/Presentation
Number 006

Background The prognosis in MS patients, in term of disability, is highly variable. At the present time, data regarding possible predictors of long-term follow-up disability are conflicting.

Objective

Design/Methods 303 MS patients belonging to an initial cohort of 597 MS patients who had participated in a multicenter cross sectional MRI and clinical study in May 2002 were clinically reevaluated in April 2011. Clinical data were: age, age at disease onset, disease duration at baseline, disability at baseline and at follow- up (FU) as indicated by the EDSS score. The same MRI protocol was performed in all subjects using the same MRI machine. Lesion load, global brain volume, white matter (WM) and grey matter (GM) volumes were measured at baseline by fully automated, operator-independent, multi-parametric segmentation method.To identify MRI and clinical predictors for long-term disability we performed statistical analysis on 241 patients who had a relapsing remitting (RR) course at baseline. A backward Stepwise regression model was used to a p value <0.05 was considered statistically significant.

Results multivariate analysis showed that progression of disease from RR to SP and reaching the milestone of EDSS 4 and worsening of EDSS during FU were positively correlated to baseline GM atrophy. With respect to clinical parameters progression of disease from RR to SP course and reaching the milestone of EDSS 4 were positevely correlated to EDSS at baseline. Survival analysis showed that the milestone 4 was reached faster in SP patients with respect to the all population of RR and SP patients.

Conclusions our findings confirm in a large cohort of RR MS patients with a long FU period, that GM atrophy is the most sensible MRI predictor of clinical disability and disease progression.

Authors/Disclosures
Gioacchino Tedeschi, MD (University of Campania "L. Vanvitelli") PRESENTER	Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Luigi Lavorgna	No disclosure on file
	No disclosure on file
Isabella L. Simone (Insitute of Neurologist, Univerisity of Bari Italy)	No disclosure on file
Alessandro D'Ambrosio	No disclosure on file
Roberta Lanzillo	Roberta Lanzillo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck, Biogen. Roberta Lanzillo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen, Roche, Novartis.
Carmelo Graffagnino, MD (Duke University Medical Center)	No disclosure on file
Antonio G. Gallo, MD	No disclosure on file
Giuseppe Salemi, MD (Istituto Di Neuropsichiatria)	No disclosure on file
Francesco Patti, MD	Dr. Patti has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. The institution of Dr. Patti has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Almirall. Dr. Patti has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Meyers. Dr. Patti has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson and Johnson. The institution of Dr. Patti has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. The institution of Dr. Patti has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Patti has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. The institution of Dr. Patti has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Patti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Almirall, Bayer, Biogen, Bristol Meyers and Squibb Merck, Roche, Sanofi, TEVA. Dr. Patti has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for University of Catania and AISM/FISM, Fondazione Italiana Sclerosi Multipla. Dr. Patti has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology.
Vincenzo Brescia Morra, MD (Universita Federico II - Napoli)	Dr. Brescia Morra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Brescia Morra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Brescia Morra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Brescia Morra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Brescia Morra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Dr. Brescia Morra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ALMIRALL. Dr. Brescia Morra has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MERK. Dr. Brescia Morra has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MERK. The institution of Dr. Brescia Morra has received research support from FISM. Dr. Brescia Morra has a non-compensated relationship as a PI with FISM that is relevant to AAN interests or activities.
Mario Zappia, MD (Università Degli Studi Di Catania- Dept of Medical & Surgical Sciences)	No disclosure on file
	No disclosure on file
Maria Buccafusca	No disclosure on file
Gabriella Coniglio, MD (Ospedale San Carlo)	No disclosure on file
Giovanni Savettieri, MD	No disclosure on file
Simona Bonavita	No disclosure on file

��ɫ��

��ɫ��